TNGX Latest Headlines

Guggenheim Keeps Their Buy Rating on Tango Therapeutics (TNGX)

at www.tipranks.com (Tue, 10-Nov 7:29 AM)

Canaccord Genuity Sticks to Its Buy Rating for Tango Therapeutics (TNGX)

at www.tipranks.com (Tue, 10-Nov 7:29 AM)

Tango Therapeutics GAAP EPS of -$0.39

at seekingalpha.com (Mon, 9-Nov 7:17 AM)

Tango’s vopimetostat combo posts 82% response rate in heavily pretreated pancreatic cancer, setting up a planned Phase 3 start in 1H 2027

Market Chameleon (Fri, 23-Oct 7:06 AM)